An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Piragliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 18 Sep 2007 Status changed from in progress to completed.
- 07 Dec 2006 New trial record.